Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CRS-207: Phase II data

An open-label, U.S. Phase II trial in 90 patients with metastatic pancreatic cancer was stopped early after CRS-207 plus GVAX Pancreas cancer vaccine and cyclophosphamide met the primary endpoint of improving

Read the full 317 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE